ReviewHealth economics review2025
Economic burden and cost drivers of generalized pustular psoriasis: a systematic review.
Review in Health economics review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Monotherapy with Biologics for Generalized Pustular Psoriasis: A Systematic Review of Comparative Interventional Studies with an Exploratory Network Meta-Analysis.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Generalized Pustular Psoriasis: A Cost-of-Illness and Health-Related Quality of Life Study in Italy.PharmacoEconomics - open · 2026Article
- Economic burden of Generalized Pustular Psoriasis in Malaysia: a multi-centre analysis of indirect costs.Journal of pharmaceutical policy and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generalized pustular psoriasis (GPP), as a rare type of life-threatening psoriasis with currently no effective treatment, imposes a huge economic burden on the healthcare systems. This systematic review aimed to summarize studies on the economic burden of GPP and the corresponding key cost drivers. A systematic search was conducted on PubMed, Web of Science, and Scopus for eligible studies published between 1st January 2000 and 31st December 2024. We strictly followed the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines. Among the 324 studies identified, ten eligible studies describing the direct and indirect healthcare costs of GPP across five countries were included in this review. This study demonstrated that the average annual cost associated with GPP spans a wide range, with a mean of USD 23,675 (SD:16,691) [range: 7,791 − 49,891]. Based on the pool estimation, the leading cost drivers for GPP were the costs of inpatient admissions and medications. More than half of GPP patients (54.8%) were on topical steroids, 38.8% were on systemic non-biologic agents, and 14.8% were on biologic agents. For biologic agents, the highest usage was observed in the United States, and lowest usage was observed in China. In conclusion, this systematic review highlights the significant economic burden associated with GPP globally, mainly driven by the costs of admissions and medications. The review also demonstrates the challenges in GPP treatment, including the frequent use of systemic corticosteroids and limited access to newer biologic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.